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Summary The ECOG Scale of Performance Status (PS) is widely used to quantify the functional status of
cancer patients, and is an important factor determining prognosis in a number of malignant conditions. The
PS describes the status of symptoms and functions with respect to ambulatory status and need for care. PS 0
means normal activity, PS 1 means some symptoms, but still near fully ambulatory, PS 2 means less than 50%,
and PS 3 means more than 50% ofdaytime in bed, while PS 4 means completely bedridden. An inter-observer
variability study of PS assessment has been carried out to evaluate the non-chance agreement among three
oncologists rating 100 consecutive cancer patients. Total unanimity was observed in 40 cases, unanimity
between two observers in 53 cases, and total disagreement in seven cases. Kappa statistics reveal the ability of
the observers compared to change alone and were used to evaluate non-chance agreement. Overall Kappa was
0.44, (95% confidence limits 0.38-0.51). The Kappa for PS 0 was 0.55 (0.44-0.67), while those for PS 1, 2, 3
and four were 0.48 (0.37-0.60), 0.31 (0.19-0.42), 0.43 (0.32-0.55), and 0.33 (0.33-0.45), respectively. If one
observer allocated patients to PS 0-2, then another randomly selected observed placed the patients in the
same category with a probability of 0.92. For patients with PS 3-4 the probability that the same category
would be chosen was 0.82. Overall, the non-chance agreement between observers was only moderate, when all
ECOG Performance Status groups were considered. However, agreement with regard to allocation of patients
to PS 0-2 versus 3-4 was high. This is of interest because this cut-off is often used in clinical studies.
Performance status (PS) is an assessment of the patients'
actual level of function and capability of self-care. It has
repeatedly been demonstrated that PS is an important prog-
nostic factor for survival in several major cancer forms, e.g.
breast cancer (Swenerton et al., 1979), ovarian cancer (Lund
et al., 1990), small cell lung cancer (0sterlind & Andersen,
1986), and non-small cell lung cancer (S0rensen et al., 1989).
Accordingly, PS must be taken into consideration in the
planning and evaluation ofclinical trials of cancer treatment.
It has also been suggested that PS might be used as part of
the assessment of the patients' quality of life (Ganz et al.,
1988).
Several scales for measuring PS have been suggested,
among which the most widely used are Karnofsky's Scale of
Performance Status (Karnofsky et al., 1948), and ECOG
Scale of Performance Status (Zubrod et al., 1960). In spite of
their common use there is only limited information about the
validity and reliability of these scales.
The validity relates to whether the scale actually measures
the intended subject, while reliability deals with the degree of
confidence we have in the individual measurements, and is
often described as intra- and inter-observer variability.
Only few previous trials have evaluated the validity of
Karnofsky Performance Status Scale (Mor et al., 1984; Wood
et al., 1981; Schag et al., 1984), and studies on the ECOG
Scale are even more sparse.
No intra-observer variability analysis has been reported for
any of the PS scales. In contrast, three previous papers report
on the inter-observer variability in the use of Karnofsky
Performance Status Scale (Schag et al., 1984; Yates et al.,
1980; Hutchinson et al., 1979). No other scales have been
extensively evaluated, though Conill et al. reported on the
use of the ECOG Scale of Performance Status in a group of
ambulatory patients (Conill et al., 1990).
Yates et al. (Yates et al., 1980) evaluated the Karnofsky
Scale with respect to inter-observer variability between nurses
and social workers and found a correlation coefficient of
0.69. Poor correlation among PS assessment by doctors was
reported by Hutchinson et al. (Hutchinson et al., 1979), who
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included patients requiring hemodialysis or patients admitted
to the emergency room. This might influence the results, as
the Karnofsky Scale was originally designed for use in cancer
patients.
Agreement between oncologists on the one hand and
psychologists or psychiatrists on the other was evaluated by
Schag et al. (Schag et al., 1984) in 75 cancer patients. They
found a correlation coefficient of0.89. The question of agree-
ment among oncologists was not evaluated. This issue has
been addressed in one study (Conill et al., 1990), though not
with the use of Kappa statistics for the evaluation of non-
chance agreement. The purpose of the present study was to
evaluate the reliability of the ECOG Scale of Performance
Status by measuring the non-chance agreement between three
oncologists.
Materials and methods
The three observers were oncologists working in the clinic
who otherwise had no specific training for the actual project.
The patient population was 100 consecutive in-patients at
the clinic seen on randomly selected days during the 3-month
study period. The patients were included, after informed
conset had been obtained. Each observer interviewed the
patient on the same day, usually within a 3-h period, and
scored the patient according to the ECOG Scale of Perfor-
mance Status (Table I). Each observer was blinded for the
rating of the other observers and did not see the hospital
records before rating.
Table I Eastern Cooperative Oncology Group (ECOG) scale of
performance status
Value Description
0 Normal activity
1 Symptoms, but nearly fully ambulatory
2 Some bed time, but needs to be in bed less than
50% of normal daytime
3 Needs to be in bed greater than 50% of normal
daytime
4 Unable to get out of bed
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The inter-observer agreement was evaluated using Kappa
statistics. Kappa is a coefficient of interjudge agreement for
nominal and ordinal scales (Cohen, J, 1960). It is directly
interpretable as the proportion ofjoint judgements in which
there is agreement, after chance agreement is excluded. Thus,
Kappa value indicates how much better the observers are as
compared to chance alone, and varies between -1 and + 1.
Kappa = + 1 means full agreement, Kappa = 0 indicates that
the agreement can be explained solely by chance, and Kappa
<0 is found when the observed agreement is less than
expected by chance (Cohen, J, 1960; Fleiss et al., 1979).
Kappa values above 0.40 indicate fair agreement, while
values above 0.70 point towards good agreement.
Results
Characteristics of the 100 consecutive patients who entered
the study are given in Table II. There was an equal sex
distribution in the study. Approximately equal numbers of
patients had small cell lung cancer, ovarian cancer, testicular
cancer, and other malignant diseases.
The distribution of ECOG scores for the individual ob-
servers is shown in Table III. The number of patients con-
sidered to have ECOG score 0 and 1 was similar among the
observers. Larger differences were, however, noted with
respect to ECOG scores 2, 3, and 4 (Table III). Unanimity
between all three observers was observed in 40 cases, unan-
imity between two of the observers in 53 cases, and total
disagreement in seven cases.
Kappa statistics on the inter-observer variability are shown
in Table IV. Overall Kappa in ECOG scoring between the
three observers was 0.44 (95% confidence limits 0.38-0.51).
The Kappa value was higher in the best performance status
groups, ECOG score 0 having a Kappa value of 0.55 (95%
confidence limits 0.44-0.67), and lowest in ECOG score 4,
with a Kappa value of 0.33 (95% confidence limits 0.22-
0.45). This points towards a lower agreement among obser-
vers in evaluation of patients in the poor performance status
groups than the less affected patients.
The Kappa values given above were not weighted accor-
ding to the degree of disagreement, i.e. the more serious
disagreements when observers rank the same patient as hav-
Table II Patients' characteristics
No. of patients
Total no. 100
Sex
Male 49
Female 51
Diagnosis
Small cell lung cancer 26
Ovarian cancer 25
Testicular cancer 22
Other cancer 27
Current anticancer treatment
None 52
Chemotherapy 41
Radiotherapy 7
Table III Performance status assessment by three observers in 100
cancer patients
No. of patients
ECOG Score Observer 1 Observer 2 Observer 3
0 26 22 23
1 32 33 34
2 12 13 22
3 24 21 17
4 6 11 4
Total 100 100 100
Table IV Kappa statistics for assessment of ECOG performance
status among 100 cancer patients by three observers
95% confidence
ECOG score Kappa limits
0 0.55 (0.44-0.67)
1 0.48 (0.37-0.60)
2 0.31 (0.19-0.42)
3 0.43 (0.32-0.55)
4 0.33 (0.22-0.45)
Overall Kappa 0.44 (95% confidence limits 0.38-0.51).
ing PS 0 and PS 4, respectively, were given the same weight
in the analysis as the less serious event when a patient was
ranked as PS 0 and PS 1, respectively.
However, given the considerable variations in ECOG scor-
ing between the observers, we analysed the results further by
dividing the scores into only two groups: ECOG score 0-2
versus ECOG score 3-4 (Table V). This dividing point was
chosen because it is often used as a cut-off point for inclusion
of patients in clinical studies of experimental treatments.
If one observer allocated a patient to ECOG score 0, 1, or
2, then another randomly selected observer would place the
patient in the same category (ECOG 0, 1, or 2) with a
probability of 0.92. Thus the proportion of second observers
in the study whose assessment agreed with that of the first
observer was 0.92. For patients in ECOG group 3 to 4, the
same category (ECOG 3 or 4) was chosen with a probability
of 0.82.
Discussion
In the interpretation of data on agreement rates, the original
distribution of the phenomenon in the study with respect to
frequency of normality and abnormality is crucial, and must
be taken into consideration. This hampers comparison be-
tween studies, since an overall agreement rate is the sum of
agreements about normality and abnormality. An overall
agreement rate of 80% may mean 40% of cases agreed as
normal and 40% agreed as abnormal, or 75% of cases
agreed as normal and 5% agreed as abnormal. The latter
outcome is much easier to achieve (Koran, 1975). By use of
Kappa statistics, it is possible to calculate the non-chance
agreement, and this standardised measure may be compared
between studies.
Also, in the inter-observer variability within a study, the
agreement rate of two equally skilled physicians regarding
the presence of an abnormality in a series of cases is, in part,
a function of the proportion of cases each physician con-
sideres abnormal (Spitzer & Fleiss, 1974). If two physicians
each consider halfthe cases abnormal, they will agree 25% of
the time by chance alone. If they each consider 80% of the
cases abnormal, they will agree 64% of the time by chance
alone. Hence, since the proportion of abnormal cases varies
across studies, the level of agreement by chance varies across
studies. Thus, an overall agreement rate of 80% in one study
may be 55% more than chance expectation, whereas in a
second study it is only 16% more than chance expectation
(Spitzer & Fleiss, 1974).
This phenomenon is reflected in the current study, in which
only hospitalised patients were examined, with more than
40% of the patients having ECOG score 2 or worse, and
21% to 31% of cases having ECOG score 3 or 4. This
Table V Simplified performance status assessment among 100
cancer patients by three observers
Agreement (proportion of cases with
ECOG score agreement among all three observers)
0-2 0.92
3-4 0.82PERFORMANCE STATUS ASSESSMENT 775
resulted in an overall agreement of 40% among three
observers. In contrast, Conill et al. (Conill et al., 1990)
examined a patient population with a lower frequency of
severe abnormalities, as 79% to 81% of their patients had
ECOG Performance Status 0 or 1, and only 5% to 7% had
PS 3 or 4. There was a coincidence degree of 59% in the
rating according to ECOG Performance Status by the two
observers. Contributing to the difference in agreement rates
between the present study (40% agreement) and the study by
Conill et al. (59%) is also the different number of observers,
as the more observers, the lower the inter-observer agreement
rate would be expected to be (Segall, 1960; Conn & Spencer,
1972).
The order in which the observers interviewed patients for
assessment of performance status may theoretically introduce
systematic biases if the order is not completely randomized.
In the current study, observer 1 had universally performed
the first interview with patient, while the order of interview
by observer 2 and 3 was random. However, the similar
distribution of patients in the respective performance status
classes achieved by the three observers as shown in Table III
does not point towards any systematic bias in the results.
Performance status has in recent years become a tool in
the growing field of psychometric testing of scales for
measuring quality of life among cancer patients. In the pro-
cess of developing such scales the validity is often tested by
comparing the results from rating on the quality of life scale
to the PS assessment, e.g. as described by Schipper et al.
(Schipper et al., 1984) in the evaluation of the Functional
Living Index - Cancer. This new use of the PS assessment
obviously necessitates a solid knowledge of the validity and
the reliability of the PS scale itself.
While PS assessment has traditionally been performed by
physicians, this is not necessarily the case in scales measuring
quality of life. Slevin et al. conclude from a questionnaire
study that a reliable and consistent method of measuring
quality of life in cancer patients must come from the patients
themselves (Slevin et al., 1988). Given this difference with
respect to observers of the scale, together with the inter-
observers variability in PS assessment, one should not expect
correlations between quality of life scales and PS to be very
high, even if the former scales were valid.
In conclusion, the reliability of the ECOG Scale of Perfor-
mance Status, as evaluated by the degree of inter-observer
variability, is fair, offering additional support for its wide-
spread use, for example as a prognostic factor or as an
inclusion criterium for entry into clinical trials. Agreement is
higher in patients with good performance status than in more
affected patients, a fact which must be born in mind in the
interpretation of data from trials dealing with this topic.
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